以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

8月18日，福瑞股份盘中20.0%涨停，截至09:33，报60.19元/股，成交4.1亿元，换手率3.03%，总市值 159.49亿元。 资料显示，内蒙古福瑞医疗科技股份有限公司位于内蒙古乌兰察布市集宁区解放路103号，公司是一家 专注于肝病医疗的企业，其主要业务包括投资、收购相关医疗企业，并在全球多地设有子公司和研发中 心。公司于2010年在深交所创业板上市，股票代码300049，形成了以北京为管理中心、内蒙古为制药基 地、法国巴黎为研发前沿、成都为医疗服务基地的战略布局。 截至7月10日，福瑞股份股东户数2.08万，人均流通股1.12万股。 2025年1月-3月，福瑞股份实现营业收入3.3亿元，同比增长2.35%；归属净利润2863.67万元，同比减少 32.97%。 来源：金融界 ...

福瑞股份最新一期业绩显示，截至2025一季报，公司营业总收入3.30亿元、同比增长2.35%，归属净利 润2863.67万元，同比减少32.97%，扣非净利润2970.71万元，同比减少28.05%，流动比率4.564、速动比 率4.141、资产负债率28.99%。 来源：金融界 金融界消息 截至2025年8月13日收盘，福瑞股份（300049）报收于48.84元，下跌0.75%，换手率 3.11%，成交量7.26万手，成交金额3.54亿元。 天眼查商业履历信息显示，内蒙古福瑞医疗科技股份有限公司，成立于2001年，位于乌兰察布市，是一 家以从事医药制造业为主的企业。企业注册资本26497.59万人民币，实缴资本13931.5035万人民币。公 司法定代表人为王冠一。 资金流向方面，今日主力资金净流出1037.07万元，占比成交额2.93%。其中，超大单净流出870.06万 元、占成交额2.46%，大单净流出167.01万元、占成交额0.47%，中单净流出流出1026.28万元、占成交 额2.9%，小单净流入2063.35万元、占成交额5.83%。 通过天眼查大数据分析，内蒙古福瑞医疗科技股份有限公司共对外投 ...

Group 1 - The core viewpoint of the news is that Furu Pharmaceutical (福瑞股份) has shown a slight increase in stock price, but the company is experiencing a decline in net profit and net profit after deducting non-recurring gains and losses in its latest financial report [1] - As of August 11, 2025, Furu Pharmaceutical's stock closed at 48.9 yuan, with a trading volume of 91,500 lots and a transaction amount of 451 million yuan [1] - The company's latest quarterly report indicates total operating revenue of 330 million yuan, a year-on-year increase of 2.35%, while net profit attributable to shareholders decreased by 32.97% to 28.64 million yuan [1] Group 2 - Furu Pharmaceutical has invested in 23 companies and participated in 552 bidding projects, indicating active engagement in business expansion [2] - The company holds 31 trademark registrations and 11 patents, showcasing its commitment to intellectual property [2] - Furu Pharmaceutical has obtained 17 administrative licenses, reflecting its compliance with regulatory requirements [2]

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...

8月7日早盘，医疗板块涨势又起，A股最大医疗ETF（512170）盘初冲高2%，成交额快速突破4亿元。 成份股方面，医疗器械概念股领涨，福瑞股份一度涨近8%，华大智造、英科医疗涨超6%。CXO概念普 跌，药明康德、昭衍新药跌逾1%。 | | | 分时 多日 1分 5分 15分 30分 60分 · | | | | | F9 盘前盘后 露加 九粒 画纸 工具 @ 0 | | 医疗ETF ① | | 512170 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 512170(医疗ETF) 10:10 价 0.372 涨跌 0.004(1.09%) 均价 0.372 服交量 9404 IOPV | | | | | | | | 087 | | | | | | | | 1.98% | 0.372 | | +0.004 +1.09% | | | | | | | | | | | | SSE CNY 10:10:58 文易中 | 通的方面开 | | 0.372 | | | | | | | | 0.99 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Furuya Co., which has a current PE ratio of 122.20, significantly higher than the industry average of 53.93 [1][2] - Furuya Co. has a total market capitalization of 12.123 billion yuan, ranking 109th in the medical device industry based on PE ratio [1][2] - The company experienced a net inflow of 8.6534 million yuan in main funds on August 6, but has seen a total outflow of 52.424 million yuan over the past five days [1] Group 2 - Furuya Co.'s main business includes the production and sales of drugs in the liver disease field, development and sales of diagnostic equipment, and related medical services, with its primary product being the compound tortoise shell soft liver tablets [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97% [1] - The gross profit margin for Furuya Co. stands at 76.76% [1]

Core Insights - The CSI 1000 Healthcare Index has shown significant growth, with a 13.89% increase over the past month, 24.30% over the last three months, and 27.10% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 13651.50 points [1] - The index is designed to provide a diversified investment option by selecting liquid and representative securities from each industry [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Borui Pharmaceutical (3.51%) - Tonghua Golden Horse (2.65%) - Zai Lab (2.51%) - Zhongsheng Pharmaceutical (1.75%) - Zhaoyan New Drug (1.70%) - Anke Biotechnology (1.66%) - Yipinhong (1.63%) - Zuoli Pharmaceutical (1.59%) - Furuide (1.39%) - Dongcheng Pharmaceutical (1.33%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.62%, while the Shenzhen Stock Exchange accounts for 44.38% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 36.28% - Medical devices: 19.30% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.30% - Medical commerce and services: 7.16% - Pharmaceutical and biotechnology services: 5.94% [2] Group 4: Sample Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments [2] - When a sample company is delisted, it will be removed from the index, and any mergers, acquisitions, or splits will be handled according to maintenance guidelines [2]

Group 1 - The report emphasizes the coexistence of strategic opportunities and risk challenges in the economic landscape, marking a shift from short-term recovery to long-term foundation building in policy focus [1][2] - It highlights the need for macroeconomic policies to accelerate bond issuance and ensure the stability of three key areas, while also advocating for targeted support in sectors like technology and consumption [1][2] - The report notes a renewed emphasis on boosting domestic demand by fostering new growth points in service consumption, linking the improvement of people's livelihoods directly to consumption expansion [1][2] Group 2 - The report identifies three significant breakthroughs in industrial policy, transitioning from conceptual advocacy to practical implementation, addressing market pain points, and institutionalizing capacity governance [2] - In the foreign trade sector, it discusses a balanced approach of defense and progress, promoting high-level free trade zone construction and the integration of domestic and foreign trade [2] - The report outlines a proactive approach to risk resolution, focusing on eliminating hidden debts and ensuring energy supply to safeguard people's livelihoods [2] Group 3 - Domestic economic data shows stability and resilience, with previous growth stabilization policies gradually taking effect, while new macro policies are expected to further stimulate demand [3] - The report indicates that August will be a critical period for verifying mid-year performance, with a focus on sectors and stocks that may exceed expectations [3] - It mentions that despite increased market risk factors, the positive momentum from policies remains unchanged, particularly in the technology sector, which includes areas like computing power, artificial intelligence, and consumer electronics [3] Group 4 - The report recommends a stock portfolio for August, highlighting strong performers from July, including Dingjie Zhishi (+43.58%) and Lianrui New Materials (+25.03%), among others [6] - The recommended stocks for August cover various sectors, including telecommunications, technology, pharmaceuticals, and chemicals, indicating a diversified investment strategy [6][14] - The report notes that the average increase in the recommended portfolio for July was +10.71%, outperforming major indices [6][12]

Company Overview - Furuya Co., Ltd. closed at 43.71 yuan, down 2.48%, with a rolling PE ratio of 116.75 times and a total market value of 11.582 billion yuan [1] - The company ranks 108th in the medical device industry, which has an average PE ratio of 53.65 times and a median of 37.22 times [1] Institutional Holdings - As of the first quarter of 2025, 13 institutions hold shares in Furuya Co., Ltd., all being funds, with a total holding of 6.5628 million shares valued at 213 million yuan [1] Business Focus - Furuya Co., Ltd. specializes in the production and sales of drugs in the liver disease field, development and sales of diagnostic equipment, and related medical services [1] - The company's main product is the Compound Turtle Shell Soft Liver Tablets [1] Financial Performance - In the first quarter of 2025, the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35% [1] - The net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97% [1] - The sales gross margin stood at 76.76% [1]